Prof. Edison is the Professor of Neuroscience and Clinical Professor in the Department of Brain Sciences in the Faculty of Medicine at Imperial College London. He is also an honorary Professor at Cardiff University, Wales.
He is also a Consultant at Hammersmith Hospital (Imperial College Healthcare NHS trust), London. He is the Editor-in-Chief of the journal BRAIN CONNECTIVITY, he leads Imperial College Memory Research Centre. He leads several national and international multicentre studies involving US, Canada, Europe and Australia. He leads European Working Group on neurological complications of Covid-19 and other emerging infections. He leads an international consortium to evaluate the influence of microbial infection on cognitive function and neurodegeneration.
Dr Edison’s research has focused on neuroimaging with novel molecular probes using PET (Positron Emission Tomography) and magnetic resonance imaging (MRI) techniques for imaging pathophysiological changes associated with Alzheimer’s disease and other neurodegenerative diseases. His initial work evaluated one of the first amyloid imaging agent in Alzheimer’s disease at the MRC Cyclotron Unit at Hammersmith Hospital, Imperial College London and has published seminal papers in the field. His pioneering work on the longitudinal trajectory of microglial activation gave insight into the potential novel ways of targeting microglia as a treatment for AD and highlighted the challenges.
One of his streams of work now focuses on the interplay between inflammation and immunity in neurodegenerative and neuroinflammatory disease, and how genes influence neuroinflammation. He is also evaluating the methods of modulating inflammation and amyloid in Alzheimer’s disease, and the influence of cardiometabolic factors on the development of neurodegenerative diseases by means of clinical and pre-clinical studies. In another stream of his work, he is evaluating the influence and mechanism of GLP-1 analogues in the treatment of Alzheimer’s disease and other neurodegenerative diseases. In another stream of his work, he is evaluating the mechanism by which Blood Brain Barrier dysfunction leads to neuronal damage and is evaluating novel therapeutic strategies.
He is a member of grant review body for Alzheimer’s association, US; Research Council, Norway and Swedish Research Council. He has published in high Impact journals such as Nature Reviews Nature Medicine, BMJ, Neurology, Brain, Annals of Neurology, Molecular Psychiatry, Neurology, and has received grants from the Medical Research Council, National Institute of Health-US (NIH), NIHR/HEFCE, Alzheimer’s Society, Alzheimer’s Research UK, Alzheimer’s Drug Discovery Foundation US, and other funders. He has also received grants from Novo Nordisk, GE Healthcare, Novartis, Piramal Life Sciences and Astra Zeneca. He is a consultant for different pharmaceutical companies.
